OECD Home › Science and technology › By Country › Germany
The OECD STI Outlook provides profiles of the science and innovation performance of each OECD country and certain non-members in relation to their national context and policy issues. The graphs enable countries to see some of their relative strengths and weaknesses compared to other countries.&l
For many of today’s new biomedical innovations, the distinctions between different forms of medical products such as drugs, diagnostics and devices no longer apply. Biomedicine also tends to realize its potential today through process innovation, even more than product innovation.
What impact has the crisis had on innovation and spending on research and development? How can innovation help to solve environmental and social threats? The OECD Science, Technology and Industry Scoreboard 2009 provides the data and analysis to answer these questions.
Summarises proceedings of a conference looking at examples of human genetic research databases, how they are established, how they are managed and governed, how they might be commercialised, and what the policy considerations might be.
This publication examines the innovation system in pharmaceutical biotechnology in eight OECD countries. Based on rich evidence, it draws policy recommendations to foster innovation in biopharmaceuticals advocating an integrated policy approach.
English, , 17kb
This note summarises recent developments in science, technology and innovation in Germany.
Investment in information technologies has by no means been confined to the United States and yet, average European or Japanese growth experience has been quite different.
Regulatory Developments in Xenotransplantation in Germany.